Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727477 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30727482 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL1679799 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL30435700 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL31143600 | 1.00 | PDE5A (0.75) | PDE5A | |
| SCHEMBL14283383 | 0.92 | PDE5A (0.69) | PDE5A | |
| SCHEMBL28912195 | 0.92 | PDE5A (0.72) | PDE5A | |
| SCHEMBL28417919 | 0.91 | PDE5A (0.71) | PDE5A | |
| SCHEMBL28417910 | 0.91 | PDE5A (0.71) | PDE5A | |
| SCHEMBL17283017 | 0.91 | PDE5A (0.62) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113917027-B | Optical isomer separation detection method of avanafil and intermediate thereof | 山东省药学科学院 | 2023-03-21 | — | — | CN | disclosed |
| CN-113917027-A | Optical isomer separation detection method for avanafil and intermediate thereof | 山东省药学科学院 | 2022-01-11 | — | — | CN | disclosed |
| US-9593101-B2 | Avanafil preparation method | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2017-03-14 | — | — | US | disclosed |
| US-20160362400-A1 | AVANAFIL PREPARATION METHOD | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-12-15 | — | — | US | disclosed |
| US-9453001-B2 | Avanafil preparation method | SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (CN) | 2016-09-27 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359371-B2 | Bicyclic substituted pyrimidine compounds | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| WO-2015177807-A1 | A PROCESS FOR THE PREPARATION OF AVANAFIL AND ITS NOVEL INTERMEDIATES | WANBURY LTD. (IN) | 2015-11-26 | — | — | WO | disclosed |
| US-20030229095-A1 | Sexual disorders | TANABE SEIYAKU CO., LTD. | 2003-12-11 | — | — | US | disclosed |
| EP-1366760-A1 | TABLETS QUICKLY DISINTEGRATED IN ORAL CAVITY | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-10-16 | — | — | US | disclosed |
| CN-1440393-A | cyclic compound | TANABE SEIYAKU CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| EP-1316316-A1 | PREPARATIONS FOR ORAL ADMINISTRATION | TANABE SEIYAKU CO., LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| CN-1374953-A | 6-membered aromatic ring compound containing nitrogen | TANABE SEIYAKU CO (JP) | 2002-10-16 | — | — | CN | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | PDE5A 4/4885 |
| US-20030229095-A1 | Sexual disorders | PDE3B, PDE3A, PDE2A | PDE5A 4/4885 |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | PDE5A, PDE3A, PDE2A | PDE5A 1/4885 |
| US-20160362400-A1 | AVANAFIL PREPARATION METHOD | MTAP, RNGTT, DNMT1 | PDE5A 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.